Teprotumumab

Targets (1)

This drug entry is a **stub** and has not been fully annotated. It is scheduled to be annotated soon.

IDENTIFICATION

Name	Teprotumumab
Accession Number	DB06343
Type	Biotech
Groups	Investigational
Biologic Classification	Protein Based Therapies Monoclonal antibody (mAb)
Description	A fully human IgG1 type monoclonal antibody directed against the human insulin-like growth factor-I receptor.
Protein chemical formula	Not Available
Protein average weight	Not Available
Sequences	Not Available
Synonyms	Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human monoclonal heavy chain), disulfide with human monoclonal light chain, dimer
External IDs	R-1507 / R1507 / RG-1507 / RG1507 / RO-4858696 / RO-4858696-000 / RO-4858696000 / RO4858696 / RO4858696-000 / RV-001 / RV001
Categories	Amino Acids, Peptides, and Proteins Antibodies Blood Proteins Globulins Immunoglobulins Immunoproteins Proteins Serum Globulins
UNII	Y64GQ0KC0A
CAS number	1036734-93-6

PHARMACOLOGY

Indication	Investigated for use/treatment in solid tumors.
Pharmacodynamics	Not Available
Mechanism of	R1507 (formerly called Roche 1) is a fully human antibody which targets the Insulin-like Growth

factor-1 Receptor (IGF-1R). The IGF-1R molecule has been shown to be important in tumor growth

for an antibody therapeutic approach. [Genmab Website]

TARGET	ACTIONS	ORGANISM
U Insulin-like growth factor 1 receptor	Not Available	Humans

Absorption	Not Available
Volume of distribution	Not Available
Protein binding	Not Available
Metabolism	Not Available
Route of elimination	Not Available
Half life	Not Available
Clearance	Not Available
Toxicity	Not Available
Affected organisms	Not Available
Pathways	Not Available
Pharmacogenomic Effects/ADRs	Not Available

INTERACTIONS

Drug Interactions

ALL DRUGS | APPROVED | VET APPROVED | NUTRACEUTICAL | ILLICIT | WITHDRAWN | INVESTIGATIONAL | EXPERIMENTAL

Show 10 entries Search

DRUG	INTERACTION
Abciximab	The risk or severity of adverse effects can be increased when Abciximab is combined with Teprotumumab.
Abituzumab	The risk or severity of adverse effects can be increased when Teprotumumab is combined with Abituzumab.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Teprotumumab.
Adecatumumab	The risk or severity of adverse effects can be increased when Adecatumumab is combined with Teprotumumab.
Aducanumab	The risk or severity of adverse effects can be increased when Teprotumumab is combined with Aducanumab.
Afelimomab	The risk or severity of adverse effects can be increased when Afelimomab is combined with Teprotumumab.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teprotumumab.
Alirocumab	The risk or severity of adverse effects can be increased when Teprotumumab is combined with Alirocumab.

	Amatuximab.
AMG 108	The risk or severity of adverse effects can be increased when AMG 108 is combined with Teprotumumab.

Showing 1 to 10 of 242 entries ‹ 1 2 3 4 5 … 25 ›

Food Interactions Not Available

REFERENCES

General References Not Available

External Links Wikipedia Teprotumumab

CLINICAL TRIALS

Clinical Trials Show 10 entries Search

PHASE	STATUS	PURPOSE	CONDITIONS	COUNT
1	Completed	Basic Science	Cancer, Breast	1
1	Completed	Treatment	Diabetic Macular Edema (DME)	1
1	Completed	Treatment	Neoplasms	2
1	Terminated	Treatment	Neoplasms	2
2	Completed	Treatment	Cancer, Breast	1
2	Completed	Treatment	Non-Squamous Non-Small Cell Lung Cancer	1
2	Completed	Treatment	Ophthalmopathy, Thyroid-Associated / Thyroid Associated Ophthalmopathy	1
2	Completed	Treatment	Sarcomas	1
2	Terminated	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC)	1
3	Active Not Recruiting	Treatment	Graves' Orbitopathy / Thyroid Eye Disease	1

Showing 1 to 10 of 11 entries ‹ 1 2 ›

PHARMACOECONOMICS

Manufacturers Not Available

Packagers Not Available

Dosage forms Not Available

Prices Not Available

Patents Not Available

PROPERTIES

State Solid

Experimental Properties Not Available

TAXONOMY

Kingdom	Organic Compounds
Super Class	Organic Acids
Class	Carboxylic Acids and Derivatives
Sub Class	Amino Acids, Peptides, and Analogues
Direct Parent	Peptides
Alternative Parents	Not Available
Substituents	Not Available
Molecular Framework	Not Available
External Descriptors	Not Available

TARGETS

1. Insulin-like growth factor 1 receptor Details

Kind	Protein
Organism	Humans
Pharmacological action	Unknown
General Function	Protein tyrosine kinase activity
Specific Function	Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involv...
Gene Name	IGF1R
Uniprot ID	P08069
Uniprot Name	Insulin-like growth factor 1 receptor
Molecular Weight	154791.73 Da

Drug created on March 19, 2008 10:25 / Updated on November 02, 2018 06:16

This project is supported by the **Canadian Institutes of Health Research** (award #111062), **Alberta Innovates - Health Solutions**, and by **The Metabolomics Innovation Centre (TMIC)**, a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by **Genome Alberta**, **Genome British Columbia**, and **Genome Canada**, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is